The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Promethazine Hydrochloride / Phenylephrine Hydrochloride
Pronunciation: proe-METH-a-zeen HYE-droe-KLOR-ide/FEN-il-EF-rin HYE-droe-KLOR-ide
Class: Antihistamine, Decongestant
- Syrup phenylephrine hydrochloride 5 mg/promethazine hydrochloride 6.25 mg per 5 mL
Competitively antagonizes histamine at H 1 -receptor sites and produces sedative as well as antiemetic effects.Phenylephrine
Stimulates postsynaptic alpha-receptors, resulting in rise in arterial peripheral vasoconstriction.
Indications and Usage
Temporary relief of upper respiratory tract symptoms, including nasal congestion, associated with allergy or the common cold.
Treatment of lower respiratory tract symptoms, including asthma; patients with hypertension or peripheral vascular insufficiency; patients receiving MAOIs; known hypersensitivity or an idiosyncratic reaction to promethazine or other phenothiazines; allergy to any component of the product; children younger than 2 y of age.
Dosage and AdministrationMaximum dose
The following maximum doses are according to the prescribing information:Adults and Children 12 y of age and older
Promethazine 37.5 mg/day; phenylephrine 60 mg/day (30 mL/day).Children 6 to 11 y of age
Promethazine 37.5 mg/day; phenylephrine 30 mg/day (30 mL/day).Children 2 to 5 y of age
Promethazine 18.75 mg/day; phenylephrine 15 mg/day (15 mL/day).Adults FDA-approved uses Upper respiratory tract symptoms
For specific dosing by product, refer to the individual manufacturer prescribing information.Usual dosage
5 mL every 4 to 6 h.Maximum dose
Promethazine 37.5 mg/day; phenylephrine 60 mg/day (30 mL/day).Children FDA-approved uses Upper respiratory tract symptoms
For specific dosing by product, see the individual manufacturer prescribing information.12 y of age and older Usual dosage
5 mL every 4 to 6 h.Maximum dosage
Promethazine 37.5 mg/day; phenylephrine 60 mg/day (30 mL/day).6 to 11 y of age Usual dosage
2.5 to 5 mL every 4 to 6 h.Maximum dose
Promethazine 37.5 mg/day; phenylephrine 30 mg/day (30 mL/day).2 to 5 y of age Usual dosage
1.25 to 2.5 mL every 4 to 6 h.Maximum dosage
Promethazine 18.75 mg/day; phenylephrine 15 mg/day (15 mL/day).Younger than 2 y of age
Use is contraindicated. Safety and efficacy not established.Elderly
Use with caution, usually staring at low end of dosage range, because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
Per the Beers list, promethazine may have potent anticholinergic properties. Nonanticholinergic antihistamines are preferred in elderly patients when treating allergic reactions. Promethazine is also considered a high-risk medication for elderly patients according to the Centers of Medicare and Medicaid Services.Hepatic function impairment
Use with caution.
- Give with food or milk if GI upset occurs. Use dosing spoon or syringe for pediatric doses.
Store syrup between 59° and 86°F. Protect from light.
Drug InteractionsPhenylephrine Alpha-adrenergic blockers (eg, phentolamine)
Decreased pressor response.Anorexiants (eg, amphetamines, phenylpropanolamine)
Synergistic adrenergic response.Atropine
Reflex bradycardia may be blocked or pressor response enhanced.Beta-adrenergic blockers (eg, propranolol)
Cardiostimulating effects may be blocked.Bronchodilators, sympathomimetic agents
Tachycardia or other arrhythmias may occur.Ergot derivatives
Excessive increase in BP may occur.MAOIs (eg, isocarboxazid)
Because acute hypertensive crisis may occur, coadministration of these agents is contraindicated.Tricyclic antidepressants
Pressor effects of phenylephrine may be increased.Promethazine Alcohol, barbiturates, other CNS depressants, narcotic analgesics, sedative-hypnotics, tranquilizers, or tricyclic antidepressants
Sedative effects of promethazine are additive with these agents.Anticholinergics
May decrease action of promethazine.Barbiturate anesthetics
Coadministration with promethazine may increase the risk of neuromuscular excitation and hypotension.Epinephrine
Because promethazine may reverse the vasopressor effect of epinephrine, do not use epinephrine to treat promethazine-associated overdose.MAOIs
Coadministration with promethazine may prolong and intensify anticholinergic effects; may cause hypotension and extrapyramidal effects.
Laboratory Test Interactions
False-negative or false-positive interpretations of diagnostic pregnancy tests based on immunological reactions between human chorionic gonadotropin (hCG) and anti-hCG; increased blood glucose tests.
Bradycardia, decreased and increased BP, faintness, tachycardia.
Anxiety, dizziness, nervousness, restlessness, tremor, weakness.Promethazine
Catatonic-like states, confusion, convulsive seizures, disorientation, dizziness, drowsiness, euphoria, excitation, extrapyramidal symptoms (including oculogyric crisis, tongue protrusion, and torticollis), fatigue, hallucinations, hysteria, incoordination, insomnia, lassitude, nervousness, sedation, somnolence, tremor.
Dermatitis, photosensitivity, urticaria.
Blurred vision, diplopia, nasal stuffiness, tinnitus.
Dry mouth, nausea, vomiting.
Agranulocytosis, leukopenia, thrombocytopenia, thrombocytopenic purpura.
Jaundice (including cholestatic).
Asthma, potentially fatal apnea and respiratory depression.
Angioneurotic edema, paradoxical reactions (including abnormal movements and hyperexcitability with agitated behavior, delirium, nightmares, and respiratory distress in some patients), potentially fatal NMS.
Because of potential for fatal respiratory depression, do not administer promethazine to children younger than 2 y of age. Administer with caution to children older than 2 y of age.
Category C .
Contraindicated in children younger than 2 y of age.
Use with caution, usually starting at low end of dosage range, because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
Special Risk Patients
Use with caution in patients with bone marrow suppression, narrow-angle glaucoma, pyloroduodenal obstruction, stenosing peptic ulcer, urinary bladder obstruction caused by symptomatic prostatic hypertrophy or narrowing of the bladder neck, arteriosclerosis, thyroid disease, diabetes mellitus, CV disease, or hepatic function impairment.
Extrapyramidal symptoms that can occur secondary to promethazine may be confused with the CNS signs of undiagnosed primary disease (eg, encephalopathy, Reye syndrome). Avoid use in children whose signs and symptoms may suggest Reye syndrome or other hepatic diseases.
Neuroleptic malignant syndrome
Has occurred and is potentially fatal. Signs and symptoms include altered mental status, diaphoresis, hyperpyrexia, irregular BP and pulse, muscle rigidity, and tachycardia.
Seizure threshold may be lowered; use with caution in persons with known seizure disorders or when given in combination with narcotics or local anesthetics that may also affect seizure threshold.
Avoid use in patients with history of sleep apnea.
Cerebral hemorrhage, convulsions, headache, hypertension, ventricular premature beats and short paroxysms of ventricular tachycardia, vomiting.Promethazine
Ataxia, athetosis, extensor plantar reflexes, hyperreflexia, hypertonia, mild depression of CNS and CV system to profound hypotension, respiratory depression, unconsciousness, and sudden death. Stimulation may be evident, especially in children and elderly patients. Convulsions, dry mouth, fixed dilated pupils, flushing, GI symptoms, paradoxical reaction characterized by hyperexcitability and nightmares in children.
- Advise patient to take prescribed dose every 4 to 6 h as needed.
- Advise caregiver to use dosing spoon or syringe when giving suspension to children.
- Advise patient to take with food or milk if GI upset occurs.
- Advise patient that if a dose is missed, to take it as soon as remembered unless it is nearing time for next dose. Caution patient to not double the dose to catch up.
- Advise patient that if allergy symptoms are not controlled, not to increase the dose of medication but to inform health care provider.
- Caution patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
- Advise patient to avoid alcohol and other CNS depressants because of risk of excessive sedation.
- Caution patient not to take any OTC antihistamines or decongestants while taking this medication unless advised by health care provider.
- If patient is to have allergy skin testing, advise patient not to take the medication for at least 6 days before skin testing.
- Caution patient that medication may cause sensitivity to sunlight and to avoid unnecessary exposure to ultraviolet (UV) light (eg, sunlight, tanning booths) and to use sunscreen and wear protective clothing when exposed to UV light until tolerance is determined.
- Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: abnormal muscle movements, unusual sensitivity to sunlight, nervousness, dizziness, excessive drowsiness.
Copyright © 2009 Wolters Kluwer Health.